Critical Appraisal of Gefitinib in the Treatment of Non-Small Cell Lung Cancer
The leading cause of death from malignant tumors worldwide is lung cancer. Before the development of molecularly targeted therapy, chemotherapy with platinum-based doublets was considered as the standard first-line treatment in advanced non-small cell lung cancer (NSCLC) patients. The introduction o...
Main Authors: | Yung-Hung Luo, Yu-Chin Lee, Jacqueline Whang-Peng, Yuh-Min Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2015-09-01
|
Series: | Journal of Cancer Research and Practice |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2311300616300763 |
Similar Items
-
The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer
by: Shih-Chieh Chang, et al.
Published: (2011-06-01) -
Gefitinib: a pharmacoeconomic profile of its use in patients with Non Small Cell Lung Cancer EGFR+
by: Viola Sacchi
Published: (2011-06-01) -
LPIN1 Induces Gefitinib Resistance in EGFR Inhibitor-Resistant Non-Small Cell Lung Cancer Cells
by: Jung Hee Cho, et al.
Published: (2022-04-01) -
EGFR Gene Mutation Statuses in Advanced Non-small Cell Lung Cancer Patients and Their Influence on Effect of Gefitinib
by: Wei ZHONG, et al.
Published: (2012-09-01) -
Not COVID-19, Don’t Overlook Pneumocystis in Patients on Gefitinib!
by: Jérémy Barben, et al.
Published: (2021-02-01)